Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.

The present disclosure provides methods of treating inflammatory lung conditions such as COVID-19 with a fusion protein comprising a vasoactive intestinal peptide (VIP) and an elastin-like peptide.

The present disclosure provides methods of treating inflammatory lung conditions such as COVID-19 with a fusion protein comprising a vasoactive intestinal peptide (VIP) and an elastin-like peptide.

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistence in the body, solubility, and bioavailability.

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.